Sydney Campbell
Psychiatric/Mental Health · Naples, FLNPI 1053182972
Payments from drug & device makers
Across 114 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$402
- Otsuka America Pharmaceutical, Inc.$303
- Takeda Pharmaceuticals U.S.A., Inc.$217
- Neurocrine Biosciences, Inc.$206
- Axsome Therapeutics, Inc.$204
- Noven Therapeutics, LLC$189
- plus $856 from 11 others
What the payments were for
- Food & beverage$2,378100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $402 |
| Otsuka America Pharmaceutical, Inc. | 14 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $217 |
| Neurocrine Biosciences, Inc. | 7 | $206 |
| Axsome Therapeutics, Inc. | 9 | $204 |
| Noven Therapeutics, LLC | 11 | $189 |
| Lundbeck LLC | 5 | $122 |
| Johnson & Johnson | 6 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $107 |
| Teva Pharmaceuticals USA, Inc. | 4 | $92 |
| Alkermes, Inc. | 4 | $87 |
| Tris Pharma Inc | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Corium, LLC | 5 | $67 |
| Almatica Pharma LLC | 2 | $39 |
| Neos Therapeutics, LP | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
How this compares
$2,378 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 171 | $5,007 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 36 | $1,257 |
| Methylphenidate Hcl | 38 | $1,110 |
| Aripiprazole | 16 | $356 |
| Alprazolam | 51 | $312 |
| Bupropion XlBupropion Hcl | 27 | $257 |
| Trazodone Hcl | 30 | $216 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $186 |
| Clonazepam | 25 | $177 |
| Prazosin Hcl | 11 | $102 |
| Lamotrigine | 13 | $52 |
| Escitalopram Oxalate | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Naples
- Melanie OrbenNaples$19K
- Sara AschebrookNaples$12K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.